NICE recommends once-daily LIXIANA for preventing stroke and systemic embolism

The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help prevent strokes and systemic embolism in patients suffering from the heart rhythm disorder atrial fibrillation with those over-75 a particular risk factor. NICE has issued a Final Appraisal Determination (FAD) for Lixiana (edoxaban) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation with the draft guidance stating: “Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors”. Alongside being 75 and over, these